A Multicenter, Open-label, Single-arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Neonates With Repeated Electroencephalographic Seizures

Trial Profile

A Multicenter, Open-label, Single-arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Neonates With Repeated Electroencephalographic Seizures

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 13 Aug 2018

At a glance

  • Drugs Brivaracetam (Primary) ; Brivaracetam (Primary)
  • Indications Neonatal seizures
  • Focus Pharmacokinetics
  • Acronyms PETITE
  • Sponsors UCB Biopharma
  • Most Recent Events

    • 01 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Aug 2018.
    • 01 Jul 2018 Planned End Date changed from 20 Nov 2020 to 1 Jan 2021.
    • 01 Jul 2018 Planned primary completion date changed from 1 Oct 2020 to 1 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top